188 related articles for article (PubMed ID: 6805950)
1. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
[TBL] [Abstract][Full Text] [Related]
4. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
[TBL] [Abstract][Full Text] [Related]
5. Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.
Eagan RT; Creagan ET; Rubin J; O'Connell MJ; Kovach JS
Cancer Treat Rep; 1980; 64(8-9):993-5. PubMed ID: 6778613
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
7. Phase I study of pentamethylmelamine.
Goldberg RS; Griffin JP; McSherry JW; Krakoff IH
Cancer Treat Rep; 1980; 64(12):1319-22. PubMed ID: 6781746
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of teroxirone.
Neidhart JA; Derocher D; Grever MR; Kraut EH; Malspeis L
Cancer Treat Rep; 1984 Sep; 68(9):1115-9. PubMed ID: 6478450
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
12. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
Muindi JR; Newell DR; Smith IE; Harrap KR
Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of Baker's antifol in metastatic sarcoma.
Thigpen JT; O'Bryan RM; Benjamin RS; Coltman CA
Cancer Treat Rep; 1977 Nov; 61(8):1485-7. PubMed ID: 922752
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
16. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.
Ames MM; Richardson RL; Kovach JS; Moertel CG; O'Connell MJ
Cancer Res; 1990 Jan; 50(1):206-10. PubMed ID: 2104537
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
18. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
19. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
20. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
